异喹胍氧化表型与肺癌易感性
Debrisoquine oxidation phenotype and susceptibility to lung cancer.
作者信息
Speirs C J, Murray S, Davies D S, Biola Mabadeje A F, Boobis A R
机构信息
Department of Clinical Pharmacology, Royal Postgraduate Medical School, London.
出版信息
Br J Clin Pharmacol. 1990 Jan;29(1):101-9. doi: 10.1111/j.1365-2125.1990.tb03608.x.
Abstract
- It has been suggested that poor metabolisers of debrisoquine are at reduced risk of developing lung cancer from smoking cigarettes. This has been investigated in 82 patients with established cancer of the lung. 2. The frequency of poor metaboliser subjects was not different from that in the normal population. 3. There was no tendency for subjects with lung cancer to metabolise debrisoquine more rapidly than non-cancer subjects. 4. It is concluded that debrisoquine metabolic phenotype is not a good predictor of risk of developing lung cancer in the population at large.
摘要
- 有研究表明，异喹胍代谢能力差的人因吸烟患肺癌的风险较低。对82例确诊为肺癌的患者进行了此项研究。2. 代谢能力差的受试者的频率与正常人群无异。3. 肺癌患者代谢异喹胍的速度没有比非癌症患者更快的趋势。4. 得出的结论是，异喹胍代谢表型不能很好地预测一般人群患肺癌的风险。
相似文献
1
Debrisoquine oxidation phenotype and susceptibility to lung cancer.异喹胍氧化表型与肺癌易感性
Br J Clin Pharmacol. 1990 Jan;29(1):101-9. doi: 10.1111/j.1365-2125.1990.tb03608.x.
2
Evidence for the polymorphic oxidation of debrisoquine in the Thai population.泰国人群中异喹胍多态性氧化的证据。
Br J Clin Pharmacol. 1990 Feb;29(2):244-7. doi: 10.1111/j.1365-2125.1990.tb03627.x.
3
Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype.
Cancer Res. 1989 Jul 1;49(13):3675-9.
4
Lung cancer and the debrisoquine metabolic phenotype.
J Natl Cancer Inst. 1990 Aug 1;82(15):1264-72. doi: 10.1093/jnci/82.15.1264.
5
Polymorphic oxidation of debrisoquine in lung cancer patients.
Eur J Cancer. 1991;27(2):158-61. doi: 10.1016/0277-5379(91)90477-u.
6
The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
Genet Epidemiol. 1989;6(4):517-24. doi: 10.1002/gepi.1370060406.
7
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.异喹胍氧化表型与普萘洛尔的药代动力学和药效学之间的关系。
Br J Clin Pharmacol. 1984 Jun;17(6):679-85. doi: 10.1111/j.1365-2125.1984.tb02403.x.
8
Genetically determined oxidation capacity and the disposition of debrisoquine.遗传决定的氧化能力与异喹胍的代谢
Br J Clin Pharmacol. 1983 Apr;15(4):443-50. doi: 10.1111/j.1365-2125.1983.tb01528.x.
9
Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype.美托洛尔在白种人和尼日利亚人中的立体选择性代谢——与异喹胍氧化表型的关系。
Br J Clin Pharmacol. 1989 May;27(5):613-6. doi: 10.1111/j.1365-2125.1989.tb03424.x.
10
Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.日本人群中三种测试探针（美托洛尔、异喹胍和司巴丁）代谢率之间与遗传决定的氧化多态性的相关性。
Br J Clin Pharmacol. 1990 Jan;29(1):111-5. doi: 10.1111/j.1365-2125.1990.tb03609.x.
引用本文的文献
1
Association between genetic polymorphisms of the cytochromes P-450 (1A1, 2D6, and 2E1) and the susceptibility to pancreatic cancer.细胞色素P-450（1A1、2D6和2E1）基因多态性与胰腺癌易感性之间的关联。
Korean J Intern Med. 1997 Jun;12(2):128-36. doi: 10.3904/kjim.1997.12.2.128.
2
The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
Eur J Clin Pharmacol. 1997;51(5):389-93. doi: 10.1007/s002280050219.
3
Advances in mechanisms of activation and deactivation of environmental chemicals.环境化学物质激活与失活机制的进展
Environ Health Perspect. 1993 Apr;100:169-76. doi: 10.1289/ehp.93100169.
4
The rationale for case-control methodology in epidemiological studies of cancer risk (response to Speirs et al., 1990).癌症风险流行病学研究中病例对照方法的基本原理（对斯皮尔斯等人1990年文章的回应）
Br J Clin Pharmacol. 1990 Jul;30(1):149-50. doi: 10.1111/j.1365-2125.1990.tb03756.x.
5
Debrisoquine oxidation phenotype and susceptibility to lung cancer.异喹胍氧化表型与肺癌易感性
Br J Clin Pharmacol. 1990 Oct;30(4):653-6. doi: 10.1111/j.1365-2125.1990.tb03832.x.
6
Inborn 'errors' of drug metabolism. Pharmacokinetic and clinical implications.
Clin Pharmacokinet. 1990 Oct;19(4):257-63. doi: 10.2165/00003088-199019040-00001.
7
Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer.异喹胍氧化多态性与肺癌之间不存在相关性。
Br J Clin Pharmacol. 1991 May;31(5):533-6. doi: 10.1111/j.1365-2125.1991.tb05575.x.
8
Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer.异喹胍的氧化多态性与人类结直肠癌无关。
Eur J Clin Pharmacol. 1991;40(5):525-7. doi: 10.1007/BF00315234.
9
Metabolism of debrisoquine and susceptibility to breast cancer.异喹胍代谢与乳腺癌易感性
Breast Cancer Res Treat. 1991 Mar;18(1):43-8. doi: 10.1007/BF01975442.
10
Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.肺癌患者中细胞色素P-450IID6、谷胱甘肽S-转移酶Mu类和芳胺N-乙酰转移酶的突变基因。
Clin Investig. 1992 Mar-Apr;70(3-4):307-19. doi: 10.1007/BF00184667.
本文引用的文献
1
The significance of cell type in relation to the aetiology of lung cancer.细胞类型与肺癌病因学的关系
Br J Cancer. 1957 Mar;11(1):43-8. doi: 10.1038/bjc.1957.6.
2
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.对英国白人人群中异喹胍氧化遗传多态性的家系及群体研究。
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
3
Chemical carcinogenesis.化学致癌作用
N Engl J Med. 1981 Dec 3;305(23):1379-89. doi: 10.1056/NEJM198112033052304.
4
The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.运用分析双峰分布的新方法对人司巴丁和异喹胍代谢的遗传控制。
J Med Genet. 1983 Oct;20(5):321-9. doi: 10.1136/jmg.20.5.321.
5
Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.代谢氧化表型作为肺癌易感性的标志物。
Nature. 1984;312(5990):169-70. doi: 10.1038/312169a0.
6
Oxidation phenotyping in alcoholics with liver disease of varying severity.
Alcohol Clin Exp Res. 1984 Sep-Oct;8(5):435-41. doi: 10.1111/j.1530-0277.1984.tb05697.x.
7
Assessment of lung cancer risk factors by histologic category.按组织学类别评估肺癌危险因素。
J Natl Cancer Inst. 1984 Aug;73(2):383-9. doi: 10.1093/jnci/73.2.383.
8
A reappraisal of histopathology in lung cancer and correlation of cell types with antecedent cigarette smoking.
Am Rev Respir Dis. 1973 May;107(5):790-7. doi: 10.1164/arrd.1973.107.5.790.
9
A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.一项关于决定异喹胍多态性羟化的遗传和环境因素的家族研究。
Clin Pharmacol Ther. 1985 Oct;38(4):394-401. doi: 10.1038/clpt.1985.193.
Zotero 插件